United States-based Therapeutics Solutions International Inc (OTC Markets: TSOI) is planning to use its clinical-stage cancer immunotherapy StemVacs for the treatment of COVID-19 patients, it was reported on Monday.

The firm had earlier filed data with the US FDA that indicated that treatment of cancer patients with the product resulted in improved activity of a type of immunological cell named 'natural killer' cells.

'natural killer' cells have been seen to to inhibit SARS-CoV-2 and firms such as Celularity have received approval from the FDA to use pre-made 'natural killer' cells for the treatment of COVID-19 as part of clinical trials.